Literature DB >> 2548065

86Rb(K) influx and [3H]ouabain binding by human platelets: evidence for beta-adrenergic stimulation of Na-K ATPase activity.

K Turaihi1, M A Khokher, M A Barradas, D P Mikhailidis, P Dandona.   

Abstract

Although active transport of potassium into human platelets has been demonstrated previously, there is hitherto no evidence that human platelets have an ouabain-inhibitable Na-K ATPase in their membrane. The present study demonstrates active rubidium (used as an index of potassium influx), 86Rb(K), influx into platelets, inhibitable by ouabain, and also demonstrates the presence of specific [3H]ouabain binding by the human platelet. This 86Rb(K) influx was stimulated by adrenaline, isoprenaline, and salbutamol, but noradrenaline caused a mild inhibition. Active 86Rb(K) influx by platelets was inhibited markedly by timolol, mildly by atenolol, but not by phentolamine. Therefore, active 86Rb(K) influx in human platelets is enhanced by stimulation of beta adrenoceptors of the beta 2 subtype. The platelet may therefore replace the leukocyte in future studies of Na-K ATPase activity. This would be a considerable advantage in view of the ease and rapidity of preparation of platelets.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548065     DOI: 10.1016/0026-0495(89)90065-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis.

Authors:  A Chan; R Shinde; C C Chow; C S Cockram; R Swaminathan
Journal:  BMJ       Date:  1991-11-02

2.  Glucagon stimulation of hepatic Na(+)-pump activity and alpha-subunit phosphorylation in rat hepatocytes.

Authors:  C J Lynch; K M McCall; Y C Ng; S A Hazen
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

3.  Pravastatin has no direct effect on transmembrane cationic transport systems in human erythrocytes and platelets.

Authors:  P Lijnen; V Petrov; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.